positive
Recently
Eli Lilly Posts Strong Q4 2025 Earnings on Obesity Drug Demand
Eli Lilly’s Q4 2025 earnings beat expectations, supported by strong obesity and diabetes drug sales.
Eli Lilly reported strong fourth quarter 2025 earnings and driven by sustained demand for its obesity and diabetes treatments. Revenue growth was led by higher sales of GLP-1 drugs, while operating margins improved due to scale and pricing power. The company reaffirmed its growth outlook and citing expanded manufacturing capacity and continued global demand for its flagship therapies across major international markets.